

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Government Owned Inventions Available for License: Establishment and Characterization of the A1847 Human Ovarian Carcinoma Line

AGENCY: National Institutes of Health, HHS.

ACTION: Notice.

SUMMARY: The National Cancer Institute (NCI) seeks licensees for a tumorigenic cell line, A1847, from a patient with metastatic ovarian cancer. As a BRCA1 deficient cell line, it serves as a model to researchers studying cell cycle regulation, tumor suppression and effective drugs aiding in repair of DNA damage.

FOR FURTHER INFORMATION CONTACT: Mutations, Inquiries related to this license opportunity should be directed to: Suna Gulay French, Ph.D., Technology Transfer Manager, NCI, Technology Transfer Center, Email: suna.gulay@nih.gov or Phone: 240-276-7424.

SUPPLEMENTARY INFORMATION: Mutations, such as loss of function, in the BRCA1 gene increase the risk of developing ovarian cancer. In its early stages, ovarian cancer may not cause any definitive symptoms but can rapidly progress within a year to advanced stage. This metastatic growth can occur by shedding cancerous cells into peritoneal fluid, often associated with epithelial ovarian cancer, its most common type. While treatments exist, it is limited by the development of drug resistance that is not succumbed to damage in cell death.

The National Cancer Institute (NCI) researchers derived a metastatic ovarian carcinoma cell line, A1847, from a 50-year-old female. It was established as a continuous tumorigenic cell line and characterized by isozyme phenotype, short tandem repeat (STR) analysis and karyotypically with modal number 68 and 3 marker chromosomes. This cell line may be used to identify therapeutic targets and to screen drug candidates against ovarian cancer.

NCI is seeking parties to nonexclusively license the A1847 human ovarian carcinoma cell line. "This Notice is in accordance with 37 CFR 404.4 Authority to grant licenses."

NIH Reference Number: E-137-2023-0.

Related Technologies: E-018-2020-0. *Product Type:* Research Material/ Tool.

Therapeutic Area(s): Oncology.

Publications:

- Standing, D., et al. Selective targeting of IRAK1 attenuates low molecular weight hyaluronic acid-induced stemness and non-canonical STAT3 activation in epithelial ovarian cancer. (PMID 38796478).
- Sethi, G., et al. An RNA interference lethality screen of the human druggable genome to identify molecular vulnerabilities in epithelial ovarian cancer. (PMID 23056589).
- Godwin, A.K., et al. High resistance to cisplatin in human ovarian cancer cell lines is associated with marked increase of glutathione synthesis. (PMID 1348364.)

Potential Commercial Applications:

- Tool to conduct preclinical proof-of-concept studies required for commercial development of anti-cancer agents and targeted therapies in ovarian cancer.
- Research model to investigate epithelial ovarian cancer.
- Research model for mechanistic studies of ovarian cancer and BRCA1-deficient tumors.

Competitive Advantages:

- Well-characterized metastatic ovarian cancer cell line.
- Tumorigenic cell line to generate animal models of metastatic ovarian cancer for commercial and research development.

Collaboration Opportunity:

Researchers at the NCI seek licensing for the A1847 ovarian cancer cell line.

Dated: June 10, 2026.

Richard U. Rodriguez,

Associate Director, Technology Transfer Center, National Cancer Institute.

[FR Doc. 2026-12070 Filed 6-15-26; 8:45 am]

BILLING CODE 4140-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Center for Scientific Review; Notice of Closed Meetings

Pursuant to section 1009 of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: Center for Scientific Review Special Emphasis Panel; Contracts: Alcohol Registry.

Date: July 1, 2026.

Time: 1:00 p.m. to 3:30 p.m.

Agenda: To review and evaluate contract proposals.

Address: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892.

Meeting Format: Virtual Meeting.

Contact Person: Vanessa S. Boyce, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Rm. 4185, MSC 7850, Bethesda, MD 20892, (301) 402-3726, boycevs@csr.nih.gov.

Name of Committee: Center for Scientific Review Special Emphasis Panel; Neurovascular, Blood-brain Barrier, and Clearance Pathways.

Date: July 14-15, 2026.

Time: 9:00 a.m. to 6:00 p.m.

Agenda: To review and evaluate grant applications.

Address: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892.

Meeting Format: Virtual Meeting.

Contact Person: Nilkantha Sen, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892, (301) 496-9223, nilkantha.sen@nih.gov.

Name of Committee: Center for Scientific Review Special Emphasis Panel; Fellowships: Musculoskeletal and Oral Sciences.

Date: July 14, 2026.

Time: 9:00 a.m. to 9:00 p.m.

Agenda: To review and evaluate grant applications.

Address: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892.

Meeting Format: Virtual Meeting.

Contact Person: Robert Gersch, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 800K, Bethesda, MD 20817, (301) 402-4789, robert.gersch@nih.gov.

Name of Committee: Center for Scientific Review Special Emphasis Panel; Preclinical Discovery and Validation of Pharmacotherapeutic and Immunotherapeutic Agents for Non-Cancer Disorders.

Date: July 14, 2026.

Time: 9:00 a.m. to 6:00 p.m.

Agenda: To review and evaluate grant applications.

Address: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892.

Meeting Format: Virtual Meeting.

Contact Person: Andrea Samantha Gobin, Ph.D., Scientific Review Officer,

Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892, (301) 480-4959, andi.gobin@nih.gov.

Name of Committee: Center for Scientific Review Special Emphasis Panel; Biodata Management and Computational Modeling.

Date: July 14, 2026.

Time: 9:30 a.m. to 6:30 p.m.

Agenda: To review and evaluate grant applications.

Address: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892.

Meeting Format: Virtual Meeting.

Contact Person: Christopher Ryan Mahone, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Dr., Room 710F, Bethesda, MD 20892, (240) 338-9679, mahonecr@csr.nih.gov

Name of Committee: Center for Scientific Review, Special Emphasis Panel; RFA Panel: Technologies and Instrumentation for Recording and Modulation in the Nervous System.

Date: July 14, 2026.

Time: 9:30 a.m. to 8:00 p.m.

Agenda: To review and evaluate grant applications.

Address: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892.

Meeting Format: Virtual Meeting.

Contact Person: Cristina Backman, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 5211, MSC 7846, Bethesda, MD 20892, (301) 480-9069, cbackman@mail.nih.gov.

Name of Committee: Center for Scientific Review, Special Emphasis Panel; RFA Panel: Animal and biological Material Resource Centers and Resource-related Projects.

Date: July 14, 2026.

Time: 10:00 a.m. to 6:30 p.m.

Agenda: To review and evaluate grant applications.

Address: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892.

Meeting Format: Virtual Meeting.

Contact Person: Marie-Jose Belanger, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Rm. 6188, MSC 7804, Bethesda, MD 20892, 301-435-1267, belangerm@csr.nih.gov.

Name of Committee: Center for Scientific Review Special Emphasis Panel; Fellowships: Infectious Diseases and Immunology.

Date: July 14-15, 2026.

Time: 10:00 a.m. to 5:00 p.m.

Agenda: To review and evaluate grant applications.

Address: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892.

Meeting Format: Virtual Meeting.

Contact Person: Louis A. Rosenthal, Ph.D., Scientific Review Officer, Center for Scientific Review, 6701 Rockledge Drive, 710-C, Bethesda, MD 20892, (301) 496-8947, rosenthalla@nih.gov.

Name of Committee: Center for Scientific Review, Special Emphasis Panel; Member Conflict: Topics on Autoimmunity, Immunology and Transplantation.

Date: July 14, 2026.

Time: 11:00 a.m. to 7:30 p.m.

Agenda: To review and evaluate grant applications.

Address: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892.

Meeting Format: Virtual Meeting.

Contact Person: Marci Scidmore, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892, (240) 627-3255, marci.scidmore@nih.gov.

Name of Committee: Center for Scientific Review, Special Emphasis Panel; Fellowships: Kidney, Urology, and Skin.

Date: July 14, 2026.

Time: 12:30 p.m. to 6:00 p.m.

Agenda: To review and evaluate grant applications.

Address: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892.

Meeting Format: Virtual Meeting.

Contact Person: Ryan G. Morris, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, RM 721-B, Bethesda, MD 20892, (301) 451-1322, ryan.morris@nih.gov.

(Catalogue of Federal Domestic Assistance Program Nos. 93.306, Comparative Medicine; 93.333, Clinical Research, 93.306, 93.333, 93.337, 93.393-93.396, 93.837-93.844, 93.846-93.878, 93.892, 93.893, National Institutes of Health, HHS)

Dated: June 11, 2026.

Denise M. Santeufemio,

Supervisory Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2026-12074 Filed 6-15-26; 8:45 am]

BILLING CODE 4140-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Submission for OMB Review; 30-Day Comment Request; NIH Extramural Harassment Web Form (Office of the Director, Office of Extramural Research)

AGENCY: National Institutes of Health, HHS.

ACTION: Notice.

SUMMARY: In compliance with the Paperwork Reduction Act of 1995, the National Institutes of Health (NIH) has submitted to the Office of Management and Budget (OMB) a request for review and approval of the information collection listed below.

DATES: Comments regarding this information collection are best assured of having their full effect if received by July 16, 2026.

ADDRESSES: Written comments and recommendations for the proposed information collection should be sent within 30 days of publication of this notice to www.reginfo.gov/public/do/PRAMain. Find this particular information collection by selecting "Currently under 30-day Review—Open for Public Comments" or by using the search function.

FOR FURTHER INFORMATION CONTACT: To request more information on the proposed project or to obtain a copy of the data collection plans and instruments, contact: Dr. Patricia Valdez, Chief Extramural Research Integrity Officer, Office of Extramural Research, National Institutes of Health, 6705 Rockledge Dr, Room 705-C, Bethesda, Maryland 20892 or call non-toll-free number (301) 451-2160 or email your request, including your address to: patricia.valdez@nih.gov. Formal requests for additional plans and instruments must be requested in writing.

SUPPLEMENTARY INFORMATION: This proposed information collection was previously published in the **Federal Register** on March 12, 2026, pages 12203-12204 (91 FR No. 48) and allowed 60 days for public comment. No public comments were received. The purpose of this notice is to allow an additional 30 days for public comment.

The Office of Extramural Research (OER), National Institutes of Health, may not conduct or sponsor, and the respondent is not required to respond to any information collection that has been extended, revised, or implemented on or after October 1, 1995, unless it displays a currently valid OMB control number.